Show results for
Refine by
Crohn S Disease Equipment & Supplies In Namibia
50 equipment items found
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso2 is a preclinical program targeting Crohn’s disease. It aims to develop Christensenella gut bacteria as a safe, efficient and groundbreaking oral biotherapy. YSOPIA has identified a lead candidate to relieve Crohn’s disease associated symptoms and slow down ...
Manufactured by:3B Scientific GmbH based inHamburg, GERMANY
This model shows the usual benign and malignant changes in the colon and rectum. These include diverticula, polyps, hemorrhoids, fistulae, fissures, chronic inflammatory diseases (Crohn’s disease and ulcerative colitis), as well as intestinal cancer in various ...
Manufactured by:Enterome based inParis, FRANCE
Sibofimloc is a first-in-class, orally administered small molecule that is specifically designed to reduce the inflammatory cascade underlying Crohn’s disease and remain gut-restricted, to minimize absorption into the bloodstream. ...
Manufactured by:Ferring Pharmaceuticals based inSaint-Prex, SWITZERLAND
PENTASA® (mesalazine) is Ferring’s product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn’s ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
In collaboration with Takeda Pharmaceuticals, we are developing FIN-524 and FIN-525, orally administered, Targeted Consortia product candidates designed for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD), respectively. UC and CD are the two most common types of IBD, an autoimmune condition that causes inflammation of the ...
Manufactured by:ORGENTEC Diagnostika GmbH is part of the Sebia Group based inMainz, GERMANY
Antineutrophil cytoplasmic antibodies (cANCA) against bactericidal permeability-increasing protein (BPI), in addition to PR3 or MPO antibodies, are important serological markers in the diagnosis of a number of inflammatory, especially rheumatic and gastrointestinal diseases. Antibodies against BPI are primarily found in patients with cystic fibrosis and in patients with chronic ...
Manufactured by:Quay Pharma based inFlintshire, UNITED KINGDOM
Active ingredients that are labile or that may irritate the stomach can be coated to pass through the stomach intact. For the treatment of local diseases such as ulcerative colitis, Crohn’s disease or irritable bowel syndrome, drugs can be released at the local area of the disease. These enhanced coatings ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Briakinumab (anti-IL-12) (IL-12a & IL-12b) is a human monoclonal antibody directed against the human interleukins 12 (IL-12) and 23 (IL-23), with immunomodulating activity. It has the potential to be used in the treatment of Crohn's disease. MW: 143.86 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 ...
Manufactured by:MEDICA S.P.A. based inMedolla, ITALY
Leukocyte Adsorber LA25: cartridge for selective leukocyte adsorption in the treatment of autoimmune diseases such as Crohn's disease and drug-unresponsiveulcerative rectocolitis. The cartridge uses a proprietary adsorption technology based on MediSulfone®. ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Visilizumab (Anti-CD3) is a humanized, non-Fc receptor (FcR)-binding IgG2 monoclonal antibody (MoAb) directed against CD3 with potential immunosuppressive activity. Visilizumab has the potential to be used for ulcerative colitis and Crohn's disease research. MW : 144.62 ...
Manufactured by:Infomed SA based inMeinier, SWITZERLAND
Hemoperfusion can be used to directly remove specific substances from the blood by adsorption, a technique which fixes substances on a surface. It is of particular interest for leukocytes which are too big to be filtrated without major loss of red ...
Manufactured by:RedHill Biopharma Ltd. based inTel-Aviv, ISRAEL
RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory ...
Manufactured by:NANOLEK LLC based inMoscow, RUSSIA
Anti-tumor necrosis factor-alpha monoclonalantibody. Effective in rheumathoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, ankylosing ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 ...
Manufactured by:F Care Systems NV based inBerchem, BELGIUM
The Fistura® procedure uses radio frequency thermocoagulation to treat anal fistulas utilising the emission of electromagnetic waves at a very high frequency (4MHz), similar to the principle of a microwave. This minimally invasive technique seals the fistula tract without having to open the anal sphincter and is performed in a day-case or the outpatient setting, with minimal discomfort for ...
Manufactured by:Selleck Chemicals LLC based in, NORTH AMERICA
Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 ...